Replay available

BioLife Solutions (NASDAQ:BLFS) Q4 2020 Earnings Call

BioLife Solutions (NASDAQ:BLFS) Q4 2020 earnings call, held 2021-03-22. Watch the replay and read the transcript on 6ix.

Mon, March 22, 2021 at 4:30 PMendedReplay
BioLife Solutions (NASDAQ:BLFS) Q4 2020 Earnings Call
Company
BioLife Solutions, Inc. (NASDAQ:BLFS)
Period
Q4 2020 earnings call
Date
Mon, Mar 22, 2021, 4:30 PM ET
Replay
Watch the replay on this page · 57 min
Results news release
BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results · Mon, Mar 22, 2021

On 6ix: 6ix.com/event/biolife-solutions-inc-blfs-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Thank you for standing by and welcome to the BioLife Solutions Q4 and full year 2020 earnings call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. Should you require any further assistance, please press star 0. I would now like to hand the conference over to your host, CFO, Roderick de Greef.

0:31 Sir, please go ahead. Thanks, Lateef. Good afternoon, everyone, and thank you for joining this call. Earlier today, we issued two press releases. The first was our announcement of the signing of a definitive merger agreement to acquire Global Cooling Inc., better known as Sterling Ultracold, a leading U.S.-based developer and manufacturer of ultra-low temperature freezers. The second press release detailed our Q4 and full year 2020 financial results and operational highlights. As a reminder during this call, we may make certain projections and other forward-looking statements regarding future events, for the future financial performance of the company or its acquisitions. These statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

1:21 For a detailed discussion of the risks and uncertainties that affect the company's business and that qualifies forward-looking statements, I refer you to our periodic and other public filings filed with the SEC. Company projections and forward-looking statements are based on factors that are subject to change and therefore these statements speak only as of the date they are given. The company assumes no obligation to update any projections or forward-looking statements except as required by law. During this call, we will speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. These non-GAAP or adjusted financial metrics should not be viewed as an alternative to GAAP.

2:08 However, in light of our M&A activity, we believe that the use of non-GAAP or adjusted metrics provides investors with a clearer view of our current financial results when compared to prior periods. Now I'd like to turn the call over to Mike Rice, CEO of BioLife Solutions.

2:25 Thanks, Rod, and good afternoon, everyone. Thank you for joining our call. We're very pleased to present the background, strategic rationale, and synergies, as well as the potential financial impact of our just-announced acquisition of Sterling Ultra Cold, a company that's been in the news quite a bit these last few months due to their support of COVID-19 vaccine distribution and point-of-care storage. Before I get to Sterling, I'd like to give some color on how we finished last year. I'll provide some quantitative data, but I'll leave most of the detailed revenue presentation to Rod. To set the context, it's important to review how active the cell and gene therapy space is right now. In 2020, total funding for companies participating in the space was nearly $20 billion, a 50% increase over 2019.

3:13 Industry-sponsored clinical trials increased by 154 over 2019, and several therapeutic candidates could get approved this year. 2020 was a banner year for BioLife, with total revenue of $48 million, up 76% over 2019. 2020 media revenue grew 32% over the prior year. We gained over 200 new direct customers, with new end users across the portfolio, including Media, FAW, Evo Cold Chain, CBS Freezers, and SciSafe Storage Services. Additionally, our two largest distributors sold and shipped our preservation media products to nearly 3,500 different customers. This is truly remarkable and speaks to how well our direct sales team and distribution partners are planting seeds for future growth.

4:04 Further to our media franchise, since 2016, we've processed nearly 300 cross-reference requests for our US FDA master files to support media use in human clinical trials. In 2020, we added 63 new media customers, and we also added 75 new clinical trials using our media, including 34th quarter alone. It's not a perfect data matchup, but if we take the ARM data of 154 new clinical trials in 2020, it's possible our market share is nearly 50% of these, considering we added 75 new trials last year. We continue to believe that our media franchise of really sticky, marquee customers is the engine that we'll continue to leverage to market our growing bioproduction tools and services portfolio to. To date, our biopreservation media is used in four approved cell therapies.

4:56 Yaskata and Takaris from Kite, Bionzi from Cellgene, and Centegra from Bluebird. and Carl Sauer has also used in four new therapies that could get approved this year. These include Idacel from Celgene, Omidugacel from Gametacel, Citlacel from Janssen and Elacel from Bluebird. So we could start to see the anticipated growth in customer approvals this year and continuing for several years considering our large installed base of media customers still in the clinic and marching toward filing for approvals in various geographies. Turn into our all-star products, although the pandemic significantly limited our ability to sell on-site, in-person at customer and prospect locations, we gained 11 new customers in Q4 last year and 29 for the full year of 2020.

5:41 Coming to our Evo cold chain management platform, we've continued to gain traction and added 14 new customers in Q4 last year. The large pharma company we've been working with to secure some portion of the commercial shipments has confirmed that they've completed their regulatory update filings, citing the EVO platform in the U.S. and Europe. And we're on schedule to commence a series of monthly deliveries of EVO containers to our courier partners to support customer shipments using EVO next quarter. We believe that over time, this customer decision to de-risk cold chain management by approving more than one container and logistics provider will become the norm and we'll have a strong opportunity to compete across the landscape of cell and gene therapies. In the last few months, we also onboarded two new courier partners with BioCare and Fisher Bioservices during World Courier and Quick as approved EVO partners targeting the cell and gene therapy space.

6:35 with our CBS Freezer platform. Again, the pandemic curtailed much of our on-site selling activities. However, we finished last year on a strong note and gained 19 new customers in Q4 2020. Rounding out my recap, our biostorage services team had a very strong Q4 and full year 2020. We gained six new customers in Q4 and set the stage for significant growth this year with expansion underway in the U.S. and Europe. Starting with this call and onward, based on the guidance and requests we've directly received from several government agencies, we're now going to discuss SciSafe customers and involvement with COVID vaccines. So just a heads up for when we get to the Q&A portion of this call. In summary, we're really pleased with what we accomplished last year and are confident about our organic growth potential and how the acquisition of Sterling will take BioLife to the next level.

7:25 Now, turning to the transaction, joining Rod and me on the call today is Dusty Tenney, the current CEO of Sterling Ultra Cold, who will be joining BioLife Solutions after we close the transaction as our new president and chief operating officer. Dusty has a proven track record of scaling high growth businesses at Brooks Automation and before that at Perkin Elmer, and I'm really looking forward to his contributions in scaling the business. We're thrilled to welcome Dusty and the entire Sterling team to the BioLife family. with our acquisition of Sterling. We're now guiding 2021 total revenue in the range of $101 million to $110 million and have set our next revenue goal at $250 million within the next three to four years. I'll start off with a recap of our M&A strategy and then comment on why Sterling is such a great fit for biolife.

8:12 Recall that in August 2018, we embarked on a strategy to identify and acquire or invest in novel and potentially disruptive technologies that would broaden our tools portfolio and enable us to help our cell and gene therapy customers to decrease the potential of delivering a non-viable dose. with reimbursement being predicated on an initial and sustained response from the patient and our understanding of the many ways manufactured cell and gene therapies can be damaged during storage, shipping, and thawing, we looked at the fragmented tool supplier base and got to work. The merger with Sterling is our fifth deal in the last two years, following our acquisitions of SteroBio and the Fostar product family, Celsius Technologies, and the Evo cold chain management platform. Custom Biogenic Systems, Liquid Nitrogen Freezers, and most recently, last October, SciSafe and their Biologic Storage Services offering.

9:03 We focused on the mechanical freezer landscape since we currently don't offer that temperature range in our freezer portfolio, which is limited to minus 196 C. Mechanical freezers operate in the range from minus 20 C to minus 80 C. A key requirement of our strategy to enter the mechanical freezer market was to identify technologies that are not prone to the typical compressor failures and maintenance requirements of the current market offerings. The sterling freezer platform is novel, utilizing a very efficient sterling engine and no compressors, providing much higher reliability and uptime than standard compressor-based technologies. There are just two moving parts, and the energy consumption is a fraction of compressor-based freezers, creating significant operational benefits. These are the typical reasons that customers buy from Sterling, but the most compelling reason is that all Sterling freezer systems, the portable ULT25, the undercounter SU105, and the upright 780XLE, all have programmable ultra-low temperature ranges between minus 20 C and minus 86 C, which provides customers universal applications for their biological materials and vaccines that no other system in the world can provide.

10:13 So with this acquisition, we now have complete cold chain freezer line from minus 20C to minus 196C that fulfills 100% of the needs of cell and gene therapy developers and the broader biopharma market. The strategic fit is excellent. In addition to welcoming the 18-person strong Sterling Global direct sales team to BioLife, who will now also present our CBS liquid nitrogen freezers to customers, We have an operation and cost synergy to leverage in that SciSave is a major customer of Sterling, so we'll be supplying one operations team from another. Lastly, we'll pick up 80 patents in the acquisition related to Sterling's current and future products that will enable strong, sustained product differentiation. I would like to turn the call over to Dusty to give you a background on Sterling, and then Rod can take us through our 2020 financials and the impact of the Sterling acquisition.

11:03 Dusty? Thanks, Mike. This is a great day for Sterling's team members, customers, and shareholders. From my time at Brooks Automation and more recently at Sterling Ultra Cold, I followed the progress that Mike and the BioLite team have executed to broaden their tools portfolio and provide more value to customers and shareholders. Each of the assets BioLite acquired were targets of my own M&A list. When Mike reached out to me last fall to start a conversation about putting Sterling and BioLife together, I immediately saw the strategic fit and am really looking forward to joining BioLife as its president and COO and doing my part to further the growth of the company and build it into an even bigger and more trusted supplier of critical bioproduction products and services.

11:48 Let me give you a little background on Stirling. The company was spun out of SunPower, Inc. in 1996 to capitalize on an IP estate related to the use of Stirling engines in various industrial applications. Since that time, the company developed mechanical freezers and to date has shipped more than 10,000 systems worldwide. I joined Sterling in March 2020 after a very successful time at Brooks Automation, where I was president of its life science division and oversaw rapid growth and the completion of several acquisitions. We grew life sciences revenue from $65 million to over $300 million over five years. At Sterling, we operate a 50,000 square foot manufacturing facility southeast of Columbus in Athens, Ohio, and have an inside sales and marketing team that works in downtown Columbus. We currently employ 160 team members and have been flat-out running with the pedal down hard since last August when our upright, undercounter, and portable sterling freezers were recognized as key enabling technologies for the distribution and point-of-care storage of COVID-19 vaccines.

12:56 In 2020, our revenue breakouts were along these lines. By market segment, pharma and biotech were 71%, academic 26%, and government was 3%. By freezer model, large freezers were about 80%, portable 15%, and on-the-counter freezers 5%. And by geography, North America was about 90%, EMEA 8%, and Asia Pacific 2%. We sell through distributors, mainly BWR and via our direct sales team, who also provide support for our sales partner at BWR. Preliminary revenues for 2020 was Thank you. Thank you. I'll close with some comments on why our Sterling engine freezers are highly valued in the cell and gene therapy and broader biopharma market.

14:08 Just as with BioLife's entire portfolio, it's all about helping customers reduce risk. Sterling has engaged with multiple cell, gene, and regenerative medicine customers to provide a flexible solution and maintain the cold chain of custody, critical to maintaining the efficacy and viability of these therapies. Use cases include localized high-density upright freezers at manufacturing locations, clinical applications that leverage the undercounter system given the limited space to store therapies, and a fully mobile solution that allows couriers to transport this high biological material to its point of use while maintaining full traceability at low-to-low temperatures. Sterling has partnered with several gene and cell therapy customers and co-branded the portable Benztop ULT25 as their point of view storage. This makes it easy for their customers to maintain the biological materials that they supply to clinics at proper temperatures ranging from minus 20 to minus 86 C while bringing prominent brand recognition for repetitive purchases.

15:13 Further sterling has demonstrated that its engines can also support cryo temperatures less than minus 135 C without further invention, which creates tremendous pathways for further growth as a natural combination with the existing assets within BioLife to address the full range of ultra-low temperatures required for viable cell and gene therapy storage and distribution. This truly highlights the tremendous growth synergies that exist by combining Sterling's assets with BioLife's strong cell and gene therapy portfolio. Now I'll turn the call back over to Rod.

15:49 Thanks, Dusty. I'll start off with a review of our 2020 financial performance. Revenue for the fourth quarter totaled $14.7 million, representing a 78% increase over 2019's fourth quarter revenue of $8.3 million. Media revenue for the fourth quarter of 2020 was $8.2 million, a 58% increase over the fourth quarter of 2019. This quarter's revenue also included $662,000 of sales related to the automated thaw product line, $469,000 of evocortain-related revenue, and $3.6 million in freezers and accessories at CBS. We also reported $1.8 million in biostorage revenue related to our acquisition of SciSafe, which closed on October 1st last year.

16:40 Revenue for the full year ended December 31st, 2020, totaled $48.1 million, an increase of 76% over 2019. New year revenue for the full year of 2020 increased 32% to $31 million compared to 2019. We believe that the full year comparison is the best refraction of how media revenue is currently growing as it smooths out the quarterly lumpiness we witnessed throughout 2019 and 2020 and which we expect to continue to see in 2021. Our adjusted gross margin for the fourth quarter was 54% compared with 65% last year. For the full year of 2020, Adjusted gross margin was 58% compared to 69% in the same period in 2019.

17:29 The decrease in adjusted gross margin for both periods reflects the gross margin profile of the product lines we acquired in 2019 and 2020. In addition, based on expected growth in these product lines in 2021, we increased our fixed manufacturing overhead at our EVO and freezer operations. Adjusted operating expenses for Q4 of 2020 totaled $8.2 million compared with $4.9 million in Q4 of 2019. For the full year of 2020, adjusted operating expenses totaled $27.6 million compared with $16.8 million in 2019. The increase in both periods was primarily driven by additional operating expenses related to the acquisitions made in 2019 and 2020, as well as increased headcount and stock-based compensation expense necessary to support our overall growth objectives.

18:26 The adjusted operating loss for the fourth quarter of 2020 was $255,000 compared with operating profit of $437,000 in 2019. Our adjusted operating income for the full year of 2020 totaled $293,000 compared to $2.1 million in 2019. Our adjusted net loss for the fourth quarter of 2020 was $256,000 or negative $0.01 per diluted share compared with adjusted net income of $527,000 or $0.02 per diluted share in 2019. For the full year of 2020, adjusted net income was $351,000 or $0.01 per diluted share compared with adjusted net income of $2.6 million or $0.13 per diluted share in 2019. Adjusted EBITDA for the fourth quarter of 2020 increased 47% to $2.5 million compared with $1.7 million in the fourth year of 2019. For the full year of 2020, Adjusted EBITDA increased 41% to $8.3 million compared with $5.9 million in 2019.

19:36 And our cash balance at December 31st was $90 million. Now I'd like to make a few comments on our just announced acquisition of Sterling. This is an all-stock deal where BioLife will issue 6.6 million shares of common stock in exchange for 100% of the outstanding shares of Sterling. Based on Friday's closing share price of approximately $39, the transaction has an imputed value of approximately $258 million, including the assumption of $8.7 million of debt. Thank you very much. During diligence, Dusty and his team did a good job of articulating a clear and what we believe to be an achievable plan for significant margin improvement over the next 12 to 36 months. We expect the gross margin expansion to result from the introduction of new and higher ASB products and increased plan automation, which we expect will move gross margins into the mid to high 40s.

20:59 So while we will see some near-term margin erosion, Thank you very much. In summary, we are issuing 19.9% of our outstanding shares, which is 16.5% on a pro forma basis, to acquire a business which is a great strategic fit and which we will expect will contribute in excess of 30% of projected pro forma revenue and EBITDA this year and in the following years.

21:48 I'll conclude my remarks with our revenue guidance for 2021. So for 21, we expect to report revenue in three product categories. First is media, then freezer and thaw systems, which includes our CBS and Sterling freezer systems and thaw stock product lines, and then third, services, which includes our Evo cold chain and bio storage services. Our 2021 revenue guidance is based on current expectations for our existing business and includes the anticipated contribution from our acquisition of Sterling, which is expected to close on or before May 1st. Total revenue for 2021 is expected to be in the range of 101 to 110 million, reflecting year-over-year revenue growth 110 to 129%.

22:34 Our total revenue expectation for 2021 is comprised of the following items. The expected 2021 revenue contribution of $35 to $37 million from the Sterling product line given that we expect to close on or before May 1st. Meteor revenue is expected to be between $38 and $40 million reflecting growth of 23 to 29% over 2020 and accounting for approximately 37% of total revenue. Freezer and thaw systems revenue including the contribution from Sterling, is expected to be between 50 and 54 million, accounting for approximately 50% of total revenue.

23:27 And finally, services revenue is expected to be between 13 and 16 million, accounting for approximately 13% of total revenue. Now going to our share count, in terms of our new share count, taking into consideration the 6 million shares which will be issued in connection with the Sterling transaction, we will have 40 million shares issued in outstanding and 42.5 million shares on a fully diluted basis. Now I'll turn the call back over to Mike.

24:00 Thanks, Rob. I'd like to summarize with three key points of our investment thesis. One, we have very sticky relationships with hundreds of cell and gene therapy companies, and our media is baked into hundreds of clinical trials, with each customer therapeutic candidate estimated to generate $500,000 to $2 million in annual revenue if approved. Two, these customers trust BioLife and want to buy more from us, so we have a tremendous cross-selling leverage opportunity with the rest of our offering. and three, the Sterling Acquisition brings us proprietary products, revenue scale, and a seasoned team and leader in Dusty Tenney. I'll turn the call back over to the operator. Lateef? Thank you. As a reminder, to ask a question, you will need to press star 1 on your touch-tone telephone. Again, that's star 1 on your touch-tone telephone to ask a question.

24:53 To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from the line of Paul Knight of KeyBank. Your line is open. Hey, guys. Thanks. Nice to see you again. Likewise, Paul. Hey, Paul. Hey, Mike, first question on the core business pre-serling, and that is with your talk about a 50% share, what does the rest of the market do?

25:30 Is it homebrew? Could you talk to that share estimate?

25:36 Right on, Paul. Yeah, we believe it. It remains homebrew. We have yet to see really any entrance of either pre-formulated preservation media products from any suppliers, distributors, or anybody else that's out there. So it really is a bio-life versus homebrew battle, and we're doing great, taking share, we believe, every quarter. And then regarding Sterling with existing ops, what do you have in terms of distribution, meaning your move into direct sales, do you have direct sales, what's the headcount there, what's the plan there, and who are your key distributors? Sure, Paul. Yeah, we have in the current pre-Stirling organization about 10 folks who are involved in sales, and that's a mix of inside folks and field folks.

26:23 So call it about 10 with a couple of openings. The current distributors look like this. On the media side, again, it's the big four, as always. It's Fisher, EWR, Millipore-Sigma, and StemCell Technologies, and there are perhaps 30 or so other regional in-country distributors that do a decent job on media. with CBS Freezers. We did inherit a fairly well-known and diverse distribution team around the world with good presence, so we'll have a great time just rationalizing this, and from our perspective, it's just more food on the street, so it's all about a force multiplier to leverage the story. And what's the overlap and perceived synergy with CBS? What temperature was CBS operating in for customers, and what do you see as the positives of those two together?

27:14 Yeah, great question, Paul. So with CBS, you know, the products are limited to liquid nitrogen operating temperature range, which is minus, call it 196, right? It's the coldest extreme for the complete cessation of metabolism of biologic material. Now this combined sales team has in their bag, in their arsenal, the ability to offer any freezer that meets whatever the customer's temperature range might be from minus 20 all the way to minus 196. Okay, and then lastly, regarding the COVID benefit at Sterling, Dusty, what's your thought there? Does it dissipate as we move into the year? Do we have it visible into 22? What's your thought on the duration of COVID?

28:04 Yeah, Paul, I think, first of all, a great reconnect, and thanks for the question. I think Mike provided some context there that we're not really at liberty at this point in time, just given some of the nature of the placements that we've had with COVID to really get into the mechanics associated with that question. So we're going to have to defer on that one. Thank you. Our next question comes from the line of Chris Lynn of Cohen.

28:36 Your line is open. Hi. Thanks for taking my questions. Mike, just to start. and just the strong margin profile. Sterling Ultracode appears to be a largely instrument heavy business that is also diluted to overall margins. With this in mind, could you just elaborate why you believe BioLife Solutions is the right owner of Sterling Ultracode?

29:10 Definitely. I'll start and I'll ask Rod to reiterate some of the points in our remarks. So, Chris, for us, this is about the novelty and the disruptive potential of the Sterling portfolio and then our ability to leverage the sticky media customers to expose them to this really cool new equipment offering to solve even more of their problems. And we believe, you know, obviously with Dusty and Rod on the ops and the margin side that we'll definitely get that back to and many, many more.

30:02 of Global is not much different than CVS, so currently in the low 30s. But again, as I stated, there's a pretty clear plan that we vetted as low as we could to take those margins into the 47%, right? And once we've done that, then I think you're going to be looking at blended margins overall for the company. A few years out of mid-50s at a gross level. And based on the modeling that we've done, and we've done quite a bit both internal and using an independent source, we believe that the EBITDA margin target, adjusted EBITDA margin target that we've set for 30% is absolutely achievable with a combined entity.

30:48 And in fact, as I mentioned, it's going to be at a much higher absolute number of adjusted EBITDA.

30:57 Got it. Just another question on Sterling Ultra Cold. Could you say, you know, what Sterling Ultra Cold revenue was in 2019, so pre-COVID times? And then in terms of the revenue guidance, $35 to $37 million, could you clarify if that's a gross or net revenue figure that needs to be adjusted for potential intercompany eliminations of SciSafe purchases, Sterling freezers?

31:23 Yeah, that's a good question, Chris. So 39 million is a preliminary unaudited number for global last year in 2020. The base number this year is 60. There might be a million or two here of RAC revenue that's sold by CBS to global, and the The balance of it is going to come in the form of reduced capex on the SciSafe side when they move those freezers into the SciSafe operations.

32:05 Okay, last question for me. Mike, you referenced in your prepared remarks that there are potential therapies, well, therapies that could potentially receive FDA approval this year. Now, as we think about your 2021 media revenue guidance, does that explicitly include contributions from these new product approvals and commercial-scale manufacturing volumes associated with those launches, or would that be largely upside or a 2022 dynamic?

32:34 Thank you, Chris. and many, many more. So, I think it's important for us to think about it on a 12- to 24-month ramp post-approval for us to see the large step-up changes in revenue from those hopefully soon-to-be-approved therapies. Chris, it's Rod here.

33:22 try to provide a little additional clarity because I'm not sure I fully answered your question. So you asked 2019 revenue, sorry, 2020 revenue, $39 million. Expected global revenue for the full year of 2021 is $60 million. We have it in terms of contributing to the biolife fiscal 2021 revenue, $35 to $37 million based on the fact that we're not closing the transaction until April 30th, May 1st.

33:52 Okay, could you just share what 2019 revenue was for Sterling?

33:58 2019 revenue? Dusty, if you have that handy?

34:02 Yeah, it's 35 million, Chris. Okay, great. Thanks for taking my questions. Sure.

34:11 Thank you. Our next question comes from Jacob Johnson of Stevens. Please go ahead. Good afternoon, everybody, and congratulations on all the news. Hey, Mike. Maybe starting on the Evo side, and congratulations on the customer news there. Is there any way to give any color on the revenue potential for Evo shipping a commercial therapy? I know it's a little bit different business model, but is there any way to frame up the impact on that relationship?

34:46 Not yet, Jacob. Once we get a few more of these commercial therapies, you know, allocating or splitting their shipments, then we would hope to be in a position to do that. But this is NO1, the first one, so too soon to try to prognosticate on that.

35:01 Got it. That makes sense, Mike. And maybe just try and ask it a little bit differently. On the guidance given in 2021 for the services revenue stream, $13 million, $16 million, I guess kind of a wide range given the size of those revenues. Maybe if Rod wants to just talk about what are the kind of key swing factors for the low end and the high end of that guidance of EVO versus SciSafe?

35:30 Sure, it's two things. One on the email side, it's how quickly the large commercial customer that Mike identified earlier, how quickly they ramp up through the year. Because remember that the business model is a monthly rental program, so the number of doers that go out in a particular month, you know, if it's delayed by 90 days, it does make an impact. And the other is that what we've seen in SyFa for the last six months is that The orders that Gary over there is wrestling with are very significant orders. Whether you get one or whether you get half of one or how much of it gets into this year versus next year based on the timing of close, there's a lot of variability in that, which is the other reason we have such a relatively large range.

36:19 Got it. Thanks for that, Rod. And maybe last one for me and maybe sticking with you, Rod. Just on gross margins, you know, you talked about 50% longer term, but obviously a few moving pieces in the near term. Can you give us any kind of color on your thoughts about gross margins as we think about modeling 2021?

36:38 Yeah, I think you're going to see something in the neighborhood of low 50s.

36:47 Okay. Thanks for taking the questions. You bet. Thanks, Jacob. Thank you. Our next question comes from Suraj Kalia of Oppenheimer & Company. Your question, please. Good afternoon, everyone.

37:01 Mike, can you hear me all right?

37:02 Hi, Suraj.

37:03 Yeah, hi, Suresh. Hey, congrats on the deal, Dusty, Mike, and Rod. So a lot of information provided, Mike, and maybe if I could just parse it a little more. Rod, you were kind, and Dusty, you were kind enough to give the numbers from 2019, 20, and 21 for ULT. How much, you know, if I see from 2020 through 21, there's a significant jump. How much of that is COVID-related? And I guess to the extent that you can, what was the expected growth trajectory of ULT versus if I may consider organic bio-life, everything that is non-ULT, as you looked at the company? I guess what I'm just trying to understand is, is ULT faster growing than what your bio-life was originally?

37:53 I think in the near term, Suraj, the answer to that is yes. I think that the organic growth that we would look at is, again, in that sort of 25% to 30% range, excluding sterling. And so there's going to be a bump in the sterling revenue this year, in part related to COVID, but also in part related to just an increase in demand. and we do expect that increase in demand irrespective of any future COVID activity to continue and so therefore they'll be a significant contributor and we expect them to grow at the lower end of that range.

38:32 Got it. And Rod, for ULT this would be a point of sale model, not a recurring revenue base, correct, for ULT? That's correct. and you guys are not comfortable at this stage sharing the incremental contribution from COVID-related revenues, right? Correct. Okay. Fair enough. Hey, Rod, I know this has been beaten to death. Maybe I'll just belabor it a little more. Since 2019, you know, you'll have made a determined strategy to acquire a bunch of companies and Cross margins of the different businesses, when you look at the composite cross margins, they have taken a hit. When you integrate ULT, This thing needs to reverse pretty significantly from 30% to 55%.

39:23 Maybe you can give us some additional color. I'm just going to piggyback on the prior person's question. Give us some color. What gives you the confidence level in the midterm? You can turn the tide around to get to an adjusted 30% EBITDA margin.

39:40 So, again, it's driven by two things. One is that the current Sterling Gross Margins are in the low 30s, right? And those are expected to expand to the mid to high 40s, which would then at that point give an overall blended, you know, again, we're looking in the crystal ball a bit, so it depends on how much of the revenue is comprised of media, thought, et cetera. But the point being that if they get into the mid to high 40s, then the blended revenue Thank you for joining us. We feel very strongly that we can attain the 30%.

40:31 And if you recall, Suraj, the narrative for the last 18 months for BioLife has been that, yes, we recognize that the tradeoff was to remain a one-product pony that had a great margin profile but had serious risk with respect to customer order patterns and perhaps ultimate customer growth. And so we wanted to mitigate that by... embarking on the acquisition strategy we did, fully understanding that in the near term, and that's defined as 12 to 24 months from the time we started that strategy, we would have declining margins until the point where the revenue scale, and now my stated goal of $250 million, at that point in time, we're very comfortable talking about a 30% adjusted EBITDA margin that has a mid-50s gross margin associated with it.

41:26 Got it. Hey, Mike, one last question for you. The EVO commercial win, would love to get additional color on that. Would we be too far off in thinking about the two key commercial players that you'll have bagged, at least one of them, maybe on a different product line?

41:51 Yeah, good question, Siraj. I think rather than answer that directly, I think I'll just defer to our previous response, which is this company understands how material and important this is, significant this would be for us to be able to disclose the relationship. We're not quite there yet, working through their multi-layer approval process, but I'm confident perhaps at some point we will get that approval. But before then, out of respect for the relationship, we're just not going to disclose the name.

42:22 Got it. Gentlemen, thank you for taking my questions. on the announcement. Seems like a pretty big add to your overall business. But I'd like to ask a bit generally. You invested pretty heavily into the ultra-cold freezing and the cold chain logistics. So I'd like to touch on what you anticipate to be the key drivers for growth in this business area. Obviously, COVID-19 kind of thrust ultra-cold chain logistics into the public consciousness, but it's really just the first mRNA vaccine.

43:11 There's a lot more in the pipeline. So what are the areas where you expect to really drive growth in this respect?

43:18 Yeah, Michael, good question. I think in a nutshell, you know, sticking to our meeting within cell and gene therapy, it's going to be about the pace of approvals, right? So, you know, we all know the arm data. We know how many clinical trials are out there. We've now been really clear about our estimates of how many clinical trials our media is used in. I articulated on the call in my remarks a little earlier today that we believe that the decision by this large pharma company to split off their commercial shipments and to award parts of the business to more than one logistics partner and to use more than one container so they've got some risk mitigation we believe will be the norm over the next few years so it won't be a winner-take-all scenario and we're really, I think... Thank you very much.

44:21 All right, thank you. And then I have one more on the actual Sterling freezers themselves. So how does the energy requirement compare for Sterling versus a more traditional compressor-based freezer, and how does that kind of translate into operational cost saving?

44:38 Yeah, great question. Dusty, why don't you take that one? Yeah, I think to frame it out, Michael, the basis of our savings, which is Energy Star rating, an important element in terms of the strategy that The business was born roughly about 10 years ago. And what that does, it provides a material benefit as it compares to our compressor systems anywhere between 10% and 50% less energy being used. So when you start to think about the application of our freezers versus a traditional compressor-based freezer, The infrastructure that many of our partners have realized is the fact that they can eliminate a lot of HVAC, i.e. more cooling to offset some of the heat, but also they're getting a material benefit associated with the less energy use.

45:28 And when you start to multiply that, especially with multiple different systems, there is a significant benefit that many of our customers are experiencing by virtue of using the Sterling freezer system. Thank you. I just want to ask one more, if you don't mind. How does the target use case vary for the sterling ultracold at that 20 to 86 C range compared to the CBS nitrogen-based?

46:02 Go ahead, Dusty. Well, I think there's two applications that basically cover the entire cold chain here, Michael. So when you start to think about minus 20 to minus 86, our system, unlike any compressor-based system, can be tuned to any temperature between those respective temperature ranges. So we basically cover every single temperature point between minus 20 and minus 86. and traditionally when you take a look at the workflows, especially in the end markets that Mike and Rod talked about, there are a lot of biological materials that basically are mandated to support that in addition to the vaccines that are more prominent with regards to the temperatures that we just highlighted. When you start to think about the even colder temperatures, so the deep temperatures, A key temperature point, of course, is minus 135 C.

46:55 At minus 135 C, that's the glass transition temperature. Mike noted this in terms of the fact that biological activity is stopped, and typically this is the temperature range in which cell and gene therapies are most noted to ensure that that biological activity, especially when it gets to researchers and the cell and gene therapies that are being developed. ultimately meet the efficacy requirements that are being driven from the manufacturers. So those two temperature ranges basically are all focused on biological material, but each of those respective temperatures provide a biological benefit that customers use in the markets today, whether that be clinical trials, cell and gene therapy, biobanking, etc., and the fortunate aspect that we have here is combining those two. Now we, as Mike said, cover the entire cold chain temperature range that's ever so critical for every single biological material in the world today.

47:51 All right, thank you very much. Thanks, Michael.

47:56 Thank you. Our next question comes from Thomas Layden of the Lake Street Capital.

48:00 Your line is open.

48:02 Hey, good afternoon, guys. Thanks for taking the questions. Thank you. Just a quick one on SciSafe. During the last quarterly call, there was a suggestion there was some upside to that $2.7 million COVID deal, and you've obviously raised your guidance from 9 to 12. Is that all COVID deal, or is there other business expansion that's nestled in that increase in guidance?

48:25 Yeah, good question. probably just best to stick to our line that we're just not going to talk about COVID revenues just based on the guidance we receive from a bunch of federal agencies. So we'd like to answer and give that kind of detail, but it's a little early for us to do that.

48:41 Sure. If you can quantify, but if at least we could do kind of a qualitative answer, if you think about the Venn diagram of customer overlap, I know there's some names that were thrown out during the prepared remarks, but could you help us understand what the overlap is in customers between Sterling and the legacy BioLife businesses?

49:01 Sure. Sure, somewhat qualitatively I can say that there are some customers that do use our media and also contract with SciSafe for storage. I don't want to get into how many or who they might be.

49:17 Okay, fair enough. And then, Rod, I was wondering if you could help us a little bit with how to think through the middle of the P&L this year. Obviously there's going to be a big change to the middle for the second quarter, but could you help us think about, you know, because you're not going to be accretive until next year. Can you just help us think through what that looks like from a spending perspective?

49:43 Well, I think that here's what I can say because we purposely chose not to give guidance below the revenue and a little bit of gross margin. We've got a lot of moving parts. And so what I will say is that if you looked at the operating expenses for Q4 – Thank you. Thanks, Tom.

50:35 Thank you. Our next question comes from Mark Weisenberger, Bill Riley Securities. Please go ahead. Thank you. Good afternoon, Mark. Thanks for taking the questions, and congrats on the deal. Thank you.

50:49 I'm wondering if you could talk about the demand from non-vaccine-related players in terms of bio-storage, and has there been maybe a rush to secure space with the increase in demand from vaccines?

51:07 Yeah, I don't think we want to go there, Mark. I think we're just going to stick right to it and say we're just not going to give any granularity on SciSafe other than how Rod has articulated how we're going to report that in one of the three buckets going forward this year. Got it. Understood. In the prepared remarks, you did talk about expansion in the U.S. and Europe related to biostorage.

51:29 Could you talk about maybe some color on the location and level in the estimate we can expect?

51:34 Definitely not. Based on the guidance from the federal agencies, there's one thing we're definitely not going to talk about, and that is where we're going to be and what might be stored in those facilities. We'd like to, but that's the guidance, so we're going to respect that. Okay.

51:47 You made an interesting investment in December in Panthera Cryo Solutions.

51:53 Can you talk about what attracted you to that opportunity, how their preservation media compares to your current formulation, and with kind of worldwide marketing and distribution rights, what's the strategic opportunity there going forward? Yeah, good one. Thanks for asking. So Panthera has a particular synthetic molecule that can inhibit the formation of ice on the inside of cells during the freezing process, which is really damaging. And, you know, that whole ice formation and then water flowing out, water flowing back in can cause the membranes to go crazy and rupture, and then you have no cells left because they're dead. So this particular molecule that the Panthera folks have identified and gained access to could be seen as a potential additive to our Carl Storr family of freeze media, although we have to be clear that Carl Storr works really, really well.

52:42 So there could be some upside with certain cell types, but nevertheless, it could be something we would spike Carl Storr with to make it work even better. But I think, Mark, think about this as an offensive slash defensive play. When we have the opportunity to to help them finish the work and then to commercially exploit it. We also have the opportunity to make sure that it's not in anybody else's hands where they could simply spike a homebrew with this particular molecule and come up with something that might ultimately, based on the performance, disrupt this large cryo store's hold in the cell antigen therapy space. We think we have total optionality based on how it goes, and we're looking forward to seeing how the rest of the experiments go. Awesome, great caller. And then just one more for me.

53:27 Can you talk about the expectations for the preservation media growth in the first quarter, given that there was some pull forward last year at the onset of the pandemic, and maybe just more broadly the cadence throughout the year for the respective business lines? Thank you. Well, we don't, as you know, we don't give any quarterly color, but Rod, you can chime in if you like.

53:44 Yeah, I mean, the only thing I was going to say, Mark, really, is that Q1 is going to be a tough comp on the media side because we probably pulled in a million and a half to two million in Q1 of 20 from the COVID, which was then kind of trailed off throughout the rest of the year. So we did conclude that it was demand pull forward as opposed to some permanent safety stock on the part of our customers. So I think Q1 will be what it is, but certainly on the media side, it's a tough comp. Got it. Thank you very much.

54:21 Thanks, Mark. Frank, your next question comes from Paul Knight of KeyBank. Your line is open. Thanks for the redo. Hey, Dusty, who are your competitors in your business? We've got probably two primary competitors that I'll denote. I think Thermo is probably one, and Panasonic is the second. Where do you rank in share, do you know? I think share by geography is a little bit mixed. I would say that we're hovering around the number two position in the market.

55:09 Okay. And then, Rod, I missed the breakout on the number on a zero before Q. Sorry, you broke up. Can you repeat? What was the Estero number in the CBS revenue for Q4?

55:33 Okay, Estero was, let me find my commentary, Estero was $662,000 and the freezer business was $3.6 million. Thank you very much. You bet.

55:54 Thank you. Our next question comes from Carl Burns of Northland Capital Markets. Your line is open. Thanks for the question. Congratulations. With respect to Sterling, in addition to the obvious COVID opportunity and considering that Sterling has been growing, do you see any material opportunity from stockpiling related to contracts from DOD or other government entities like BARDA? Thanks. Yeah, well, Carl, if you're asking specifically related to COVID, we wouldn't answer that. If you mean just generally, then definitely, sure. Very much, thanks.

56:41 Thank you. At this time, I'd like to turn the call back over to CEO Mike Rice for closing remarks. Sir?

56:48 Thanks, Latif, and thanks again, everyone, for your interest in BioLife. We are really inspired to share this good news, and BioLife is now even better configured for even more continued growth. We have a very strong team here that executes every day to satisfy our customers, and the performance of this team is simply amazing. We wish all of you and your families good health and safety, and we look forward to speaking with you when we report our first quarter results tonight. Ladies and gentlemen, this concludes today's conference call.

Follow BioLife Solutions, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Chris Lynn

Analyst, Cohen & Company

Jacob Johnson

Analyst, Stephens Inc.

Suraj Kalia

Analyst, Oppenheimer & Company

Paul Knight

Analyst, KeyBank

Roderick de Greef

Chief Financial Officer

Mike Rice

Chief Executive Officer

More from BioLife Solutions, Inc.